151 related articles for article (PubMed ID: 37504341)
41. Efficacy of lorlatinib treatment in
Taketa T; Nakamura T
Clin Case Rep; 2021 Apr; 9(4):2007-2010. PubMed ID: 33936630
[TBL] [Abstract][Full Text] [Related]
42. Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase-positive lung cancer.
Tanigawa K; Mizuno K; Kamenohara Y; Unoki T; Misono S; Inoue H
Respirol Case Rep; 2019 Oct; 7(7):e00454. PubMed ID: 31285826
[TBL] [Abstract][Full Text] [Related]
43. Severe Psychosis Associated With Lorlatinib.
Kunimasa K; Wada M; Nishino K
J Thorac Oncol; 2023 Jul; 18(7):e71-e72. PubMed ID: 37348995
[No Abstract] [Full Text] [Related]
44. Novel
Gower A; Golestany B; Gong J; Singhi AD; Hendifar AE
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923899
[No Abstract] [Full Text] [Related]
45. Toxic Erythema of Chemotherapy, Vasculitic Eruption With Malignant Intertrigo Characteristics, and Superimposed Infection Post-bevacizumab Initiation.
Slater KN; Nessel T; Kartono F
Cureus; 2024 Jan; 16(1):e52816. PubMed ID: 38406049
[TBL] [Abstract][Full Text] [Related]
46. Acute worsening of glycemic control in a patient with type 2 diabetes and non-small cell lung cancer after administration of lorlatinib.
Nakano Y; Miyasato-Isoda M; Gohma I; Fujisawa T
Clin Case Rep; 2022 Jan; 10(1):e05283. PubMed ID: 35079389
[TBL] [Abstract][Full Text] [Related]
47. Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.
Facchinetti F; Friboulet L
Transl Lung Cancer Res; 2018 Apr; 7(Suppl 2):S103-S106. PubMed ID: 29782561
[No Abstract] [Full Text] [Related]
48. Lorlatinib-induced visual and auditory hallucinations: A case report.
Hakamata J; Nakada H; Muramatsu H; Masuzawa K; Terai H; Ikemura S; Fukunaga K; Aomori T
Clin Case Rep; 2021 Aug; 9(8):. PubMed ID: 34466232
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and Tolerability of
Dagogo-Jack I; Kiedrowski LA; Heist RS; Lin JJ; Meador CB; Krueger EA; Do A; Peterson J; Sequist LV; Gainor JF; Lennerz JK; Digumarthy SR
JTO Clin Res Rep; 2023 Aug; 4(8):100534. PubMed ID: 37533439
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of alectinib versus crizotinib in alk-positive non-small cell lung cancer: An update meta-analysis.
Xiong R; Fu H; Zhang Q; Li W
Pak J Pharm Sci; 2023 Mar; 36(2):365-372. PubMed ID: 37530142
[TBL] [Abstract][Full Text] [Related]
52. Indole Antitumor Agents in Nanotechnology Formulations: An Overview.
Russo E; Grondona C; Brullo C; Spallarossa A; Villa C; Tasso B
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514002
[TBL] [Abstract][Full Text] [Related]
53. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R; Benjamin DJ; Nagasaka M
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224
[TBL] [Abstract][Full Text] [Related]
54. Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion.
Zhou N; Wu M; Yuan M; Wu H; Yu S; Gao X; Wang Y
Lung Cancer; 2023 Sep; 183():107289. PubMed ID: 37542770
[TBL] [Abstract][Full Text] [Related]
55. Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
Stanzione B; Del Conte A; Bertoli E; De Carlo E; Revelant A; Spina M; Bearz A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511255
[TBL] [Abstract][Full Text] [Related]
56. Breaking the 'Undruggable' Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with
Chmielewska I; Krawczyk P; Grenda A; Wójcik-Superczyńska M; Krzyżanowska N; Gil M; Milanowski J
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509393
[No Abstract] [Full Text] [Related]
57. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosiñol L; Oriol A; Ríos R; Blanchard MJ; Jarque I; Bargay J; Hernández MT; Cabañas V; Carrillo-Cruz E; Sureda A; Martínez-López J; Krsnik I; González ME; Casado LF; Martí JM; Encinas C; de Arriba F; Palomera L; Sampol A; González-Montes Y; Cabezudo E; Paiva B; Puig N; Cedena MT; de la Cruz J; Mateos MV; San Miguel J; Lahuerta JJ; Bladé J
Blood; 2023 Nov; 142(18):1518-1528. PubMed ID: 37506339
[TBL] [Abstract][Full Text] [Related]
58. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
Zhao M; Liu S; Xie R; Zhang J; Li J
Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
[TBL] [Abstract][Full Text] [Related]
59. Network approach in liquidomics landscape.
Santini D; Botticelli A; Galvano A; Iuliani M; Incorvaia L; Gristina V; Taffon C; Foderaro S; Paccagnella E; Simonetti S; Fazio F; Scagnoli S; Pomati G; Pantano F; Perrone G; De Falco E; Russo A; Spinelli GP
J Exp Clin Cancer Res; 2023 Aug; 42(1):193. PubMed ID: 37542343
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
